Results 61 to 70 of about 43,876 (205)
British Journal of Clinical Pharmacology, EarlyView.Aim Hyponatremia is a common yet potentially serious adverse event associated with antidepressants. Identifying the antidepressant class with the least risk of hyponatremia would improve patient safety. Methods Using electronic medical records from 15 hospitals standardized into Observational Medical Outcomes Partnership Common Data Model (2003–2023 ...
Kyungyeon Jung +21 more
wiley +1 more source
Expression regulation of MAO isoforms in monocytic cells in response to Th2 cytokines [PDF]
, 2005 Background: Th2-cytokines, such as interleukins-4 and –13 (IL-4, IL-13), have been identified as alternative stimuli of monocytes/macrophages. We have recently profiled the gene-expression pattern of IL-4-teated human peripheral monocytes and found that ...
Billett, E +4 more
core
Fiber‐type soft bioelectronics for wearable and implantable sensing and therapy
BMEMat, EarlyView.Fiber‐type soft bioelectronics are emerging as versatile platforms for wearable and implantable health monitoring and therapeutic applications. These bioelectronics use organic and inorganic matrices combined with advanced fillers, which feature high conductivity, electrochemical sensitivity, softness, and biocompatibility.
Haneul Kim +5 more
wiley +1 more source
Monoamine Oxidase (MAO) as a Potential Target for Anticancer Drug Design and Development
Molecules, 2021 Monoamine oxidases (MAOs) are oxidative enzymes that catalyze the conversion of biogenic amines into their corresponding aldehydes and ketones through oxidative deamination.
Reem Aljanabi +5 more
doaj +1 more source
New Approaches to the Treatment of Age-Related Brain Disorders [PDF]
, 2017 Two novel reversible enzyme inhibitors involved in monoamine metabolism are described. The novel and reversible inhibitors are the catechol-O-methyl-transferase (COMT) inhibitor, Ro 40-7592 (3,4-dihydroxy-4'-methyl-5-nitrobenzophenone), and the monoamine
Da Prada, M.
core
Key targets for multi-target ligands designed to combat neurodegeneration [PDF]
, 2016 This article is based upon work from COST Action CM1103 “Structure-based drug design for diagnosis and treatment of neurological diseases: dissecting and modulating complex function in the monoaminergic systems of the brain”, supported by COST (European ...
Majekova, Magdalena +3 more
core +5 more sources
Registered Clinical Trials of Ayahuasca and DMT: A Scoping Review
Clinical Pharmacology &Therapeutics, EarlyView.Interest in ayahuasca and its main component, N,N‐Dimethyltryptamine (DMT), has currently moved from historical and experimental use into modern clinical development. Yet, current evidence is fragmented, and systematic mapping of trial methods and design choices remains limited.
Tijana Stojanović +4 more
wiley +1 more source
MoleculesMonoamine oxidase and xanthine oxidase inhibitors represent useful multi-target drugs for the prevention, attenuation, and treatment of oxidative damage and neurodegenerative disorders.
Antonio D’Errico +9 more
doaj +1 more source
Green Processing and Synthesis, 2022 The aim of this study was to evaluate the potential inhibitory effect of montmorillonite (MMT)-reinforced, glutaraldehyde-crosslinked PVA (polyvinyl alcohol) nanofibers loaded with root extract of Berberis lycium on monoamine oxidase A and B (MAO A and B)
Ibrahim Nihal Abdalla +3 more
doaj +1 more source
MAO-A and the EEG Recognition Memory Signal in Left Parietal Cortex [PDF]
, 2014 A key part of episodic memory, or memory for the events of our lives, is recognition memory. Recognition memory is the ability to remember previously encountered stimuli.
Curran, Tim +3 more
core +1 more source